Premium
Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer
Author(s) -
JaliliNik Mohammad,
Soltani Arash,
Moussavi Soussan,
GhayourMobarhan Majid,
Ferns Gordon A.,
Hassanian Seyed Mahdi,
Avan Amir
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26368
Subject(s) - folfox , curcumin , oxaliplatin , colorectal cancer , medicine , folinic acid , oncology , cancer , chemotherapy , irinotecan , pharmacology
Colorectal cancer (CRC) is the third most common cause of cancer‐related deaths worldwide. Hence there is a need to identify new therapeutic agents that improve the current repertoire of chemotherapeutic drugs. The antitumor activity of curcumin has been reported for several tumors, including CRC. A recent phase I trial showed that curcumin is safe and tolerable adjunct to FOLFOX (5‐fluorouracil, folinic acid and oxaliplatin) chemotherapy in patient‐derived colorectal liver metastases at doses up to 2 g daily. Another trial revealed the effect of combining curcumin with FOLFOX in patients with inoperable colorectal cancer. The aim of current review was to summarize the current knowledge about possible molecular mechanisms of curcumin in CRC with particular emphasis on preclinical and early clinical studies of colorectal cancer.